Herbal Baths for Eczema: Reading a 66-Patient Add-On Trial Carefully

Dr. Arsy Editorial Team · November 9, 2026

A 2026 randomized, double-blind trial studied a traditional herbal bath called Mushengshu as an add-on for mild-to-moderate atopic dermatitis. The study reported better short-term response rates with the herbal bath than placebo, but every participant also received foundational topical therapy. That design does not show the bath can replace standard care.^[5]

What participants received

Sixty-six patients were randomized 2:1 to the herbal bath or placebo once daily for four months. Both groups also received desonide for mild disease or triamcinolone for moderate disease, together with urea ointment, applied for the first two weeks. The primary outcome was EASI-50 at week four.

Reported outcomes

At week four, 70.5% in the herbal-bath group and 45.5% in the placebo group reached EASI-50. The report also described differences in EASI-75, EASI-90, itch, IGA and quality-of-life measures, with no adverse events reported. A 66-person study cannot exclude uncommon harms, and a multi-component herbal intervention requires attention to formulation consistency and contact-allergy risk.^[5]

Why add-on evidence is not replacement evidence

Because both groups used topical anti-inflammatory therapy and urea ointment, the study evaluated whether the bath added benefit within that regimen. It did not test herbal bathing alone against evidence-based treatment. The four-month daily schedule also raises practical questions about adherence, ingredient standardization, access and whether results generalize beyond the study setting.

Questions before trying any bath additive

• Is the exact formulation standardized and clearly labeled?
• Could fragrances, botanicals or preservatives trigger irritation or contact allergy?
• Is the skin broken, painful, infected or rapidly worsening?
• Will the bath delay or replace a prescribed treatment?
• Is there evidence for the specific product rather than the general idea of “herbal” care?

Guidelines support individualized bathing and moisturizer care but do not make every bath additive interchangeable. Discuss a new product with a clinician, especially for children, pregnancy, extensive disease or suspected infection.^[15][16][17]

Where Dr. Arsy #003 fits

Dr. Arsy Moisturizer #003 is a cosmetic moisturizer for dry, sensitive and eczema-prone skin. It was not tested in the study reviewed here and should not be described as producing the study treatment’s effects. It does not diagnose, treat, cure or prevent eczema.

Continue reading

• QY201 for Eczema: What a 200-Adult Phase 2 Trial Found
• EP262 for Atopic Dermatitis: A Well-Tolerated Phase 2 Study Without Clinical Benefit
• SHR-1819 for Eczema: Interpreting a 157-Patient IL-4 Receptor Trial
• Temtokibart and Eczema: What Targeting IL-22RA1 Showed in Phase 2a
• Related Dr. Arsy eczema research guide
• Related Dr. Arsy eczema research guide

Research and clinical references

1. QY201 phase 2 dose-finding trial in adult atopic dermatitis.
2. EP262 MRGPRX2-antagonist EASE study.
3. SHR-1819 anti-IL-4Rα phase 2 study.
4. Temtokibart IL-22RA1 phase 2a study.
5. Herbal-bath randomized trial for mild-to-moderate atopic dermatitis.
6. ICP-332 phase 2 randomized clinical trial.
7. Pumecitinib 3% gel phase 2b trial.
8. Rezpegaldesleukin REZOLVE-AD phase 2b study.
9. Ivarmacitinib phase 3 randomized clinical trial.
10. Ivarmacitinib outcomes through week 52.
11. Model-based meta-analysis of randomized atopic dermatitis treatments.
12. Meta-analysis of IL-4Rα inhibitors for atopic dermatitis.
13. Antihistamines for eczema: systematic review and network meta-analysis.
14. American Academy of Dermatology adult systemic and phototherapy guideline.
15. American Academy of Dermatology adult topical-therapy guideline.
16. American Academy of Dermatology pediatric management guideline.
17. AAAAI/ACAAI atopic dermatitis clinical guideline.
18. Lebrikizumab phase 3 ADvocate trials.
19. Tralokinumab ECZTRA 1 and ECZTRA 2 trials.
20. Dupilumab phase 3 SOLO 1 and SOLO 2 trials.
21. Upadacitinib phase 3 Measure Up 1 and 2 trials.
22. Abrocitinib phase 3 JADE MONO-1 trial.
23. Roflumilast cream INTEGUMENT trials.
24. Tapinarof cream ADORING trials.

Educational information only; not a diagnosis or personalized medical advice. Cited researchers and organizations do not endorse Dr. Arsy products.